Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
INDERIDE LA 120/50 is a fixed-dose combination of propranolol hydrochloride (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic) in extended-release capsule form. It is indicated for the management of hypertension. This combination agent provides dual antihypertensive action through beta-adrenergic blockade and diuretic-mediated sodium and water depletion.
As a legacy combination product approaching loss of exclusivity with moderate competitive pressure (30%), career growth is limited and teams are likely focused on cost management and transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job postings and an LOE-approaching lifecycle, this product offers limited career advancement opportunity and is not a focus growth area for the sponsoring company. Roles available are typically defensive, focused on maintaining existing market share and managing the transition to generic competition.
Worked on INDERIDE LA 120/50 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.